Let’s make it official
Now that both Lilly and Novo Nordisk have reported can we just make it official that when it comes to their respective diabetes franchises it’s all about GLP-1’s and insulin is just one more product they sell. Where these two legacy companies diverge is the tracks they have selected to grow their GLP-1’s. Yes diabetes is still the primary target, but Novo is weighing more heavily into the obesity market. Lilly isn’t ignoring obesity but with tirzepatide coming they are rightfully concentrating on diabetes.
Let’s again make it clear that the buzz for . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.